Mumbai: AstraZeneca AB, Sweden and Nicholas Piramal India Limited, India have signed a 'development and know-how agreement'.
Under the agreement the two companies will establish a collaboration framework for developing processes for the manufacture of intermediates, active ingredients or bulk drugs for supply to AstraZeneca.
The development and know-how agreement does not have a fixed tenure. It is envisaged to continue only as long as the two companies have products under development. If the collaboration on the development of any of the products is successful, the agreement provides for the two companies to further negotiate terms of for the supply of the product by Nicholas Piramal to AstraZeneca.